Item 1.01
Entry into a Material Definitive Agreement.
As previously disclosed, on December 6, 2016, 21st Century Oncology Holdings, Inc. (we, our, us or the Company), 21st Century Oncology, Inc. (21C), a subsidiary of the Company, and certain of the Companys other subsidiaries entered into a Forbearance Agreement relating to the Companys indenture and a Forbearance Agreement relating to the Companys credit agreement (collectively, the Forbearance Agreements), with certain of 21Cs noteholders and lenders, respectively. The Forbearance Agreements were subsequently amended on December 15, 2016. As amended, the Forbearance Agreements required, among other things, that 21C enter into a transaction support agreement with its noteholders and lenders (as applicable) no later than January 4, 2017 (the TSA Deadline).
On January 15, 2017, we entered into amendments to the Forbearance Agreements (collectively, the Amendments) to, among other things, amend the TSA Deadline to January 31, 2017. The Forbearance Agreements, as amended by the Amendments, provide that the noteholders and lenders party thereto will forbear, subject to important exceptions, until the earlier of January 31, 2017 and the occurrence of certain events (as described in the Forbearance Agreements) from exercising any rights and remedies under 21Cs indenture, notes or credit agreement, as applicable, on account of certain events of default.
In addition, on January 15, 2017, Medical Developers, LLC, an indirect wholly owned subsidiary of the Company and certain of its affiliates, entered into an amendment to the MDL Credit and Guarantee Agreement to extend the maturity date from January 15, 2017 to January 31, 2017.
2